Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood–brain barrier and target glioma

In 2009, the FDA approved bevacizumab for the treatment of adult patients diagnosed with recurrent glioblastoma. However, the poor permeability of the macromolecules across the blood–brain barrier, determined by multifactorial anatomical and physiological milieu, restricts the clinical therapeutic e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Xuemei, Wang, Hongyan, Chen, Yue, Zhou, Junfei, Liu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794332/
https://www.ncbi.nlm.nih.gov/pubmed/31617104
http://dx.doi.org/10.1186/s13568-019-0869-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794332/
https://www.ncbi.nlm.nih.gov/pubmed/31617104
http://dx.doi.org/10.1186/s13568-019-0869-3

Ejemplares similares